Form 4: Director Patrick Kristin Acquires Niagen Bioscience Stock Options
Statement of Changes in Beneficial Ownership
Director Patrick Kristin of Niagen Bioscience, Inc. acquired stock options, indicating a potential future investment in the company.
Summary
- Patrick Kristin, a Director at Niagen Bioscience, Inc. (NAGE), acquired stock options on June 24, 2026.
- The options grant the right to buy 31,746 shares of Common Stock at an exercise price of $3.45 per share.
- These options are exercisable starting June 24, 2027, and expire on June 23, 2036.
- The acquisition was made under a plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions.
- Following the transaction, Kristin beneficially owns 31,746 shares directly.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive development, as a director acquiring options indicates a belief in future stock appreciation, though it is a standard practice and not a direct financial injection.
Positives
- Director Patrick Kristin's acquisition of stock options suggests confidence in the company's future prospects.
- The acquisition is structured under a Rule 10b5-1(c) plan, indicating a pre-determined and compliant trading strategy.
Risks
- The value of the acquired options is subject to market fluctuations and the future performance of Niagen Bioscience, Inc.
- There is a risk that the stock price may not exceed the exercise price of $3.45 by the expiration date, rendering the options worthless.
Future Outlook
The acquisition of stock options by a director suggests a positive outlook on the company's future performance, as the options have value only if the stock price increases above the exercise price.
Industry Context
StockSavvy.ai notes that insider acquisition of stock options, particularly under a Rule 10b5-1 plan, is a common practice for directors to align their interests with shareholders and signal confidence in the company's long-term growth potential within the biotechnology sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan | Transaction made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 06/24/2026 | Ensures compliance with insider trading regulations and provides a structured approach to stock transactions. |
Stakeholder Impact
- Shareholders: The acquisition by a director may be viewed positively, signaling confidence, but it does not immediately impact share price or ownership structure.
- Management: Reinforces alignment between director compensation/incentives and company performance.
Next Steps
- Patrick Kristin may exercise the options on or after June 24, 2027, if the stock price is favorable.
- The company's stock performance will determine the ultimate value of these options for Patrick Kristin.
Key Dates
| Date | Description |
|---|---|
| 06/24/2026 | Earliest transaction date and date of stock option acquisition. |
| 06/24/2027 | Date from which the stock options become fully vested and exercisable. |
| 06/23/2036 | Expiration date of the stock options. |
| 06/26/2026 | Date the statement was signed. |
Keywords
stock options, insider trading, Niagen Bioscience, NAGE, Form 4, beneficial ownership, director, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.